公司最新总资产周转率为0.46次。最新存货周转率为2.76次。 公司股东户数为59.44万户，前十大股东持股数量为6.39亿股，占总股本比例为19.04%，前十大股东持 股情况如下： 2025年8月19日，欧菲光(002456.SZ)发布2025年中报。 公司最新毛利率为10.00%。最新ROE为-2.85%。 公司摊薄每股收益为-0.03元。 公司营业总收入为98.37亿元，较去年同报告期营业总收入增加3.00亿元，实现2年连续上涨，同比较去 年同期上涨3.15%。归母净利润为-1.09亿元。经营活动现金净流入为3.25亿元，较去年同报告期经营活 动现金净流入增加758.08万元，实现2年连续上涨，同比较去年同期上涨2.39%。 公司最新资产负债率为77.97%，较上季度资产负债率减少0.46个百分点。 | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 深圳市欧菲投资控股有限公司 | 8.72% | | 2 | 裕高(中国)有限公司 | 4.54% | | 3 | 巢湖市生态科技发展有限公司 | 1.63% | | 4 | 香港中央结算有限公司 | 1.23% | ...

公司最新总资产周转率为0.09次。最新存货周转率为0.53次，较去年同期存货周转率增加0.09次，实现2年连续上涨，同比较去年同期上涨21.92%。 公司最新资产负债率为18.91%。 公司最新毛利率为45.40%。最新ROE为1.67%，较去年同期ROE增加0.21个百分点。 公司摊薄每股收益为0.05元，较去年同报告期摊薄每股收益增加0.01元，同比较去年同期上涨11.28%。 2025年8月19日，尤洛卡(300099.SZ)发布2025年中报。 公司营业总收入为2.40亿元。归母净利润为3853.29万元，较去年同报告期归母净利润增加388.83万元，同比较去年同期上涨11.22%。经营活动现金净流入为 971.98万元。 公司股东户数为4.02万户，前十大股东持股数量为3.04亿股，占总股本比例为41.28%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | 1 | 王媚花 | 27.6 | | 2 | 李巍屹 | 4.53 | | 3 | 闫相宏 | 2.58 | | 4 | 李新安 | 1.47 | | 5 | 争害 | 1.04 | | ...

Core Viewpoint - Dongwu Securities issued a report on August 18, giving Runben Co., Ltd. (603193.SH) a "buy" rating based on its performance and growth potential [2] Financial Performance - In the first half of 2025, the company achieved revenue of 895 million yuan, representing a year-on-year increase of 20.3% [2] - The net profit attributable to shareholders reached 188 million yuan, reflecting a year-on-year growth of 4.2% [2] Market Dynamics - The company has balanced growth in both online and offline channels [2] - The baby care product category continues to maintain high growth, although the growth rate of mosquito repellent products was slightly lower due to weather conditions [2] Cost and Profitability - There has been some fluctuation in gross margin, with increases in financial expense ratio and selling expense ratio [2]

据证券之星公开数据整理，近期欧圣电气（301187）发布2025年中报。截至本报告期末，公司营业总收 入8.78亿元，同比上升18.89%，归母净利润1.15亿元，同比上升18.52%。按单季度数据看，第二季度营 业总收入3.53亿元，同比下降14.61%，第二季度归母净利润5353.75万元，同比下降1.43%。本报告期欧 圣电气公司应收账款体量较大，当期应收账款占最新年报归母净利润比达71.22%。 本次财报公布的各项数据指标表现一般。其中，毛利率34.42%，同比减4.61%，净利率13.1%，同比减 0.31%，销售费用、管理费用、财务费用总计1.41亿元，三费占营收比16.09%，同比增5.57%，每股净资 产5.91元，同比减23.07%，每股经营性现金流0.24元，同比减78.09%，每股收益0.45元，同比减14.93% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 7.39 亿 | 8.78亿 | 18.89% | | 归母净利润(元) | 9709.92万 | 1.15亿 | 18.52% ...

Core Viewpoint - NeurAxis, Inc. (NRXS) reported a mixed performance in Q2 2025, with revenue growth but continued net losses and margin compression, while management anticipates improved financial health with upcoming insurance coverage changes and product approvals [1][2][5][6]. Revenue and Earnings Performance - NeurAxis reported Q2 2025 revenues of $0.9 million, a 46.2% increase from $0.6 million in Q2 2024, driven by a 58% increase in unit sales due to greater adoption of the IB-Stim device [2] - Gross margin decreased to 83.6% from 88% year-over-year, attributed to deeper discounting for uninsured patients and expired inventory [2] Expense Management - Operating expenses fell by 10.2% to $2.5 million from $2.7 million, primarily due to the absence of one-time costs and lower investor relations and insurance costs [3] - The operating loss narrowed to $1.7 million from $2.2 million a year earlier, while the net loss was $1.7 million, or $0.22 per share, compared to a $2.9 million loss, or $0.42 per share, in Q2 2024 [3] Cash and Liquidity - NeurAxis ended the quarter with $5.9 million in cash, supported by a $5 million equity financing round and $1 million from warrant exercises [4] - Cash used in operations was $3.1 million for the first half of 2025, up from $2.9 million in the same period last year [4] Future Outlook - Management expects gross margins to recover as more patients gain access through commercial reimbursement with the new permanent Category I CPT code effective January 1, 2026 [5] - CEO Brian Carrico indicated that national insurance coverage and inclusion of IB-Stim in clinical guidelines will enhance patient access and revenue growth [6] Regulatory Developments - NeurAxis received FDA clearance to extend IB-Stim's indication to treat pediatric functional dyspepsia, nearly doubling its addressable market [7] - The company also secured FDA clearance for the Rectal Expulsion Device (RED) and terminated its NSS-2 Bridge license with Masimo, regaining associated intellectual property [12][13] Guidance and Expectations - Although no explicit numerical guidance was provided, executives expressed confidence in achieving breakeven in 2026, contingent on broader payer adoption of IB-Stim [10] - Management anticipates continued revenue growth in the second half of 2025, supported by further insurance policy adoption and early traction for RED [11]

Core Insights - The company reported a total revenue of 440 million yuan for the first half of 2025, an increase of 210 million yuan compared to the same period last year, marking a 91.53% year-on-year growth [1] - The net profit attributable to shareholders reached 30.69 million yuan, up by 37.82 million yuan from the previous year, achieving two consecutive years of growth [1] - The net cash inflow from operating activities was 56.70 million yuan, an increase of 54.57 million yuan year-on-year, also reflecting two consecutive years of growth [1] Financial Ratios - The latest debt-to-asset ratio stands at 18.97% [3] - The gross profit margin is 24.74%, which is an increase of 6.53 percentage points compared to the same period last year [3] - The return on equity (ROE) is 2.49%, up by 3.08 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.20 yuan, an increase of 0.25 yuan compared to the same period last year, achieving two consecutive years of growth [3] - The total asset turnover ratio is 0.30 times, an increase of 0.14 times year-on-year, reflecting an 81.89% increase [3] - The inventory turnover ratio is 2.85 times, up by 0.46 times compared to the previous year, representing a 19.20% year-on-year increase [3] Shareholder Information - The number of shareholders is 8,831, with the top ten shareholders holding a total of 95.10 million shares, accounting for 62.61% of the total share capital [3] - The largest shareholder, Luo Xingshun, holds 34.33% of the shares [3]

2025年8月18日，晓鸣股份(300967.SZ)发布2025年中报。 公司营业总收入为7.52亿元，较去年同报告期营业总收入增加3.64亿元，同比较去年同期上涨93.65%。归母净利润为1.85亿元，较去年同报告期归母净利润 增加2.14亿元，实现2年连续上涨。经营活动现金净流入为2.24亿元，较去年同报告期经营活动现金净流入增加1.64亿元，同比较去年同期上涨272.39%。 | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 魏晓明 | 42.6. | | 2 | 正大投资股份有限公司 | 12.0. | | 3 | 广州谢诺辰途股权投资管理有限公司-厦门辰途创业投资合伙企业(有限合伙) | 3.84 | | ব | 广州谢诺辰途股权投资管理有限公司-辰途第一产业股权投资基金 | 1.16 | | 5 | 北京大北农科技集团股份有限公司 | 0.70 | | 6 | 浙商银行股份有限公司-国泰中证畜牧养殖交易型开放式指数证券投资基金 | 0.57 | | 7 | 石玉盞 | 0.53 | | 8 | 杜建峰 | 0.53 | | g | 王学强 | 0.45 | ...

Core Insights - Han Yu Group (300403.SZ) reported a total operating revenue of 572 million yuan for the first half of 2025, marking an increase of 20.03 million yuan compared to the same period last year, achieving a 3.63% year-on-year growth [1] - The net profit attributable to shareholders reached 117 million yuan, an increase of 514,500 yuan year-on-year, reflecting a 0.44% growth compared to the same period last year [1] - The net cash inflow from operating activities was 114 million yuan, up by 3.32% year-on-year, with an increase of 3.66 million yuan compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio stands at 15.26%, a decrease of 1.26 percentage points from the previous quarter and a reduction of 2.76 percentage points year-on-year [3] - The latest gross profit margin is 33.56% [3] - The return on equity (ROE) is reported at 5.55% [3] Earnings Per Share and Turnover - The diluted earnings per share remained stable compared to the same period last year, with a year-on-year increase of 0.41% [3] - The total asset turnover ratio is 0.23 times, while the inventory turnover ratio is 1.52 times, which is an increase of 0.02 times year-on-year, reflecting a 1.44% growth [3] Shareholder Information - The number of shareholders is 61,400, with the top ten shareholders holding a total of 257 million shares, accounting for 42.54% of the total share capital [3] - The top shareholders include Shi Huashan with 34.3 million shares, Shi Lei with 3.05 million shares, and Wu Geming with 1.68 million shares [3]

公司最新资产负债率为48.47%。 2025年8月16日，中路股份(600818.SH)发布2025年中报。 公司最新毛利率为14.93%。最新ROE为-1.46%。 公司营业总收入为5.74亿元，较去年同报告期营业总收入增加5526.90万元，实现5年连续上涨，同比较去年同期上涨10.66%。归母净利润为-830.91万元。经 营活动现金净流入为930.64万元，较去年同报告期经营活动现金净流入增加2066.95万元。 公司摊薄每股收益为-0.03元。 公司最新总资产周转率为0.59次，较去年同期总资产周转率持平，实现4年连续上涨，同比较去年同期上涨0.61%。最新存货周转率为8.42次，较去年同期存 货周转率增加0.06次，同比较去年同期上涨0.72%。 公司股东户数为4.19万户，前十大股东持股数量为4168.65万股，占总股本比例为12.97%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 上海中路(集团)有限公司 | 7.05 | | 2 | 郭洪涛 | 1.66 | | 3 | 李文武 | 1.04 | | 4 | 牛佳伟 | ...

2025年8月16日，乐心医疗(300562.SZ)发布2025年中报。 公司营业总收入为5.21亿元，较去年同报告期营业总收入增加2276.71万元，实现2年连续上涨，同比较去年同期上涨4.57%。归母净利润为4229.04万元，较 去年同报告期归母净利润增加744.07万元，实现3年连续上涨，同比较去年同期上涨21.35%。经营活动现金净流入为4825.39万元，较去年同报告期经营活动 现金净流入增加1538.43万元，实现2年连续上涨，同比较去年同期上涨46.80%。 公司最新资产负债率为33.31%，较上季度资产负债率减少1.64个百分点，较去年同期资产负债率减少2.67个百分点。 公司最新毛利率为35.00%。最新ROE为4.19%，较去年同期ROE增加0.82个百分点。 公司摊薄每股收益为0.19元，较去年同报告期摊薄每股收益增加0.03元，实现3年连续上涨，同比较去年同期上涨21.03%。 公司最新总资产周转率为0.35次，较去年同期总资产周转率增加0.03次，实现2年连续上涨，同比较去年同期上涨9.78%。最新存货周转率为4.06次，较去年 同期存货周转率增加0.58次，实现3年连续上涨，同比 ...